Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ligand-dependent nuclear receptor-interacting factor 1 (LRIF1) is a nuclear protein that functions as a chromatin regulator, contributing to chromatin organization, epigenetic gene silencing, and chromosome segregation during mitosis[1][2][4]. LRIF1 recruits Heterochromatin protein 1 alpha (HP1α) to the centromere via a conserved PXVXL motif, a process essential for accurate chromosome alignment and segregation during cell division[1]. It also plays a role in dosage compensation through X chromosome inactivation by collaborating with SMCHD1, compacts heterochromatin, and suppresses gene expression from loci such as DUX4[2][3]. Mutations in the LRIF1 gene are associated with facioscapulohumeral muscular dystrophy type 3 (FSHD3) and its protein product interacts with the nuclear retinoic acid receptor and other chromatin-associated regulators[2][3][4]. LRIF1 is not a receptor, enzyme, transporter, or typical therapeutic target, and currently, there are no known drugs or clinical biomarkers associated with it[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ligand-dependent nuclear receptor-interacting factor 1 (LRIF1).